journal article·2020-01-01Open access

The effects and mechanisms of isoliquiritigenin loaded nanoliposomes regulated AMPK/mTOR mediated glycolysis in colorectal cancer

Gang Wang, Yang Yu, Yu-Zhu Wang, Pei-Hao Yin, Ke Xu, Heng Zhang

Abstract

In this study, isoliquiritigenin (ISL) incorporated nanoliposomes were prepared and their effects on colorectal cancer (CRC) cell lines were investigated. Herein, we sought to explore the anti-cancer mechanisms of ISL loaded nanoliposomes (ISL-NLs) on AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) pathways mediated glycolysis. Also, the key targets such as caveolin 1 (CAV1), glucose transporters and Akt/mTOR that promote glycolysis, and are activated via the induction of α-enolase (ENO1), fructose bisphosphate aldolase A (ALDOA) and monocarboxylate transporter 4 (MCT4) expressions were also investigated. It was shown that ISL-NLs significantly suppressed the proliferation and glucose uptake of CRC cell by potentially regulating the glycolysis and lactate targets as well as pathways that formed the basis of the anti-CRC effects of ISL-NLs. The mechanism underlying this effect was further validated via the regulation of some key targets such as ENO1, ALDOA, lactate dehydrogenase A (LDHA) and MCT4 in glycolysis coupled with cellular myelocytomatosis oncogene (c-myc), hypoxia-inducible factor 1-alpha (HIF-1α) in protein kinase B/mTOR (Akt/mTOR) pathways. Moreover, the AMPK proteins were identified to be up-regulated while the lactic acid production was suppressed by ISL-NLs in the CRC cells, indicating that ISL-NLs had an inhibitory effect on AMPK mediated glycolysis and lactate production. Altogether, these results have provided insights into the mechanism underlying the key role that liposomal ISL played in the multiple inhibition of AMPK and Akt/mTOR mediated glycolysis and lactate generation, which may be regulated as the alternative metabolic pathways of CRC as well as serve as adjuvant therapy for the disease.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Pharmacological Effects of Natural Compounds · Biochemical and Molecular Research · Ginseng Biological Effects and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, Shanghai Eighth People's Hospital, Jiangsu University

School of Pharmacy, Jiangsu University

Putuo Hospital, Shanghai University of Traditional Chinese Medicine

Department of General Surgery, Nanjing Lishui District People's Hospital, Zhongda Hospital Lishui Branch, Southeast University

Funding

National Natural Science Foundation of China · Shanghai Health Development Planning Commission Research Project of Traditional Chinese Medicine · Shanghai Xuhui Science and Technology Commission Research Project

References (62)

Show source-provided references
1. 10.4251/wjgo.v8.i11.79310.4251/wjgo.v8.i11.793 ↗
2. Siegel R. Cancer statistics. CA Cancer J Clin. 2013;63(1):277.
3. 10.3892/ijo.2017.402910.3892/ijo.2017.4029 ↗
4. 10.1080/15384101.2016.115837410.1080/15384101.2016.1158374 ↗
5. 10.1002/cam4.41610.1002/cam4.416 ↗
6. 10.18632/oncotarget.796010.18632/oncotarget.7960 ↗
7. 10.1371/journal.pone.016842310.1371/journal.pone.0168423 ↗
8. 10.1007/s12013-019-00870-910.1007/s12013-019-00870-9 ↗
9. 10.1016/j.tcb.2015.10.01310.1016/j.tcb.2015.10.013 ↗
10. 10.7150/jca.2829910.7150/jca.28299 ↗
11. Xiao Z, Liu S, Ai F, et al. SDHB downregulation facilitates the proliferation and invasion of colorectal cancer through AMPK functions excluding those involved in the modulation of aerobic glycolysis. Exp Ther Med. 2018;15(1):864–872.
12. 10.1002/mc.2260310.1002/mc.22603 ↗
13. 10.1039/c2mb25286d10.1039/c2mb25286d ↗
14. Long NP, Lee WJ, Huy NT, et al. Novel biomarker candidates for colorectal cancer metastasis: a meta-analysis of in vitro studies. Cancer Inform. 2016;15(Suppl. 4):11–17.
15. Wang G, Wang YZ, Yu Y, et al. Triterpenoids extracted from Rhus chinensis Mill Act against colorectal cancer by inhibiting enzymes in glycolysis and glutaminolysis: network analysis and experimental validation. Nutr Cancer. 2019;72:1–27.
16. 10.2147/CMAR.S15792510.2147/CMAR.S157925 ↗
17. 10.1186/s12885-016-2566-910.1186/s12885-016-2566-9 ↗
18. 10.1016/j.taap.2013.05.03110.1016/j.taap.2013.05.031 ↗
19. 10.1159/00043037210.1159/000430372 ↗
20. 10.1155/2013/39089010.1155/2013/390890 ↗
21. 10.1093/carcin/12.2.31710.1093/carcin/12.2.317 ↗
22. 10.1016/j.ijpharm.2019.03.03410.1016/j.ijpharm.2019.03.034 ↗
23. 10.1517/17425247.2012.67992610.1517/17425247.2012.679926 ↗
24. 10.1517/17425247.2015.102168110.1517/17425247.2015.1021681 ↗
25. 10.1016/j.aninu.2015.08.00410.1016/j.aninu.2015.08.004 ↗
26. 10.1016/j.bbrc.2015.11.06610.1016/j.bbrc.2015.11.066 ↗
27. Le DT, Jung S, Quynh NTN, et al. Inhibitory role of AMP-activated protein kinase in necroptosis of HCT116 colon cancer cells with p53 null mutation under nutrient starvation. Int J Oncol. 2019;54(2):702–712.
28. 10.1371/journal.pcbi.100658410.1371/journal.pcbi.1006584 ↗
29. 10.1016/j.cell.2008.08.02110.1016/j.cell.2008.08.021 ↗
30. 10.1073/pnas.171036611410.1073/pnas.1710366114 ↗
31. 10.1038/nrc298110.1038/nrc2981 ↗
32. 10.1038/cddis.2012.14010.1038/cddis.2012.140 ↗
33. 10.1016/j.celrep.2017.09.02610.1016/j.celrep.2017.09.026 ↗
34. 10.4161/auto.2396010.4161/auto.23960 ↗
35. 10.1074/jbc.M113.54344710.1074/jbc.M113.543447 ↗
36. 10.1016/S0302-2838(03)00090-310.1016/S0302-2838(03)00090-3 ↗
37. 10.1055/s-2001-1836110.1055/s-2001-18361 ↗
38. 10.1055/s-2005-83777910.1055/s-2005-837779 ↗
39. 10.1517/14728222.2013.75686910.1517/14728222.2013.756869 ↗
40. 10.1371/journal.pone.006856610.1371/journal.pone.0068566 ↗
41. 10.1002/ddr.2151810.1002/ddr.21518 ↗
42. 10.3390/ijms1909275210.3390/ijms19092752 ↗
43. 10.1002/jcp.2738810.1002/jcp.27388 ↗
44. 10.3390/nu910107610.3390/nu9101076 ↗
45. 10.1126/science.aaa500410.1126/science.aaa5004 ↗
46. 10.1016/j.yexcr.2017.03.04610.1016/j.yexcr.2017.03.046 ↗
47. 10.1371/journal.pone.016503810.1371/journal.pone.0165038 ↗
48. 10.4161/auto.2148710.4161/auto.21487 ↗
49. 10.1073/pnas.091131610610.1073/pnas.0911316106 ↗
50. 10.1158/0008-5472.CAN-12-044810.1158/0008-5472.CAN-12-0448 ↗
51. 10.1016/j.celrep.2014.09.03610.1016/j.celrep.2014.09.036 ↗
52. 10.1371/journal.pone.017049010.1371/journal.pone.0170490 ↗
53. 10.1146/annurev-pharmtox-010611-13453710.1146/annurev-pharmtox-010611-134537 ↗
54. 10.1016/j.jamcollsurg.2009.12.00810.1016/j.jamcollsurg.2009.12.008 ↗
55. 10.1038/nature1389610.1038/nature13896 ↗
56. 10.1016/j.canlet.2013.11.00110.1016/j.canlet.2013.11.001 ↗
57. 10.1038/nrm267210.1038/nrm2672 ↗
58. Kim N, Jeong S, Jing K, et al. Docosahexaenoic acid induces cell death in human non-small cell lung cancer cells by repressing mTOR via AMPK activation and PI3K/Akt inhibition. Biomed Res Int. 2015;2015:239764.
59. 10.1016/j.neo.2016.09.00410.1016/j.neo.2016.09.004 ↗
60. 10.1016/j.cub.2014.08.00710.1016/j.cub.2014.08.007 ↗
61. 10.1016/S0092-8674(03)00929-210.1016/S0092-8674(03)00929-2 ↗
62. 10.1016/j.molcel.2008.03.00310.1016/j.molcel.2008.03.003 ↗